Introduction
Osteoarthritis, a debilitating degenerative joint disease predominantly found in elderly individuals, has become the principal source of physical disability resulting in increased health care costs and impaired quality of life in the United States. The pathogenesis of osteoarthritis (OA) involves the progressive deterioration of cartilage tissue, but many of the underlying biochemical and pathophysiological mechanisms involved in cartilage degradation and the induction of pain in this process remain largely unknown. Recent literature has focused on understanding many of these processes, with the intention of developing novel therapies aimed at slowing and/or reversing cartilage degradation and inducing symptomatic relief. This chapter provides an overview of several biochemical mediators involved in OA, with an emphasis on reviewing pertinent factors mediating cartilage breakdown and the induction of pain in degenerative conditions.
Anatomy
Articular cartilage lines the surfaces of joints and serves several important functions, including the provision of a smooth, low-friction surface, joint lubrication, and stress distribution with load bearing (1, 2). The components of articular cartilage include an elaborate mixture of water (65-80% of wet weight), collagen (10-20% of wet weight), proteoglycans (PGs; 10-15% of wet weight), and chondrocytes (5% of wet weight) (1). The extracellular matrix (ECM) includes collagen and PGs, principally aggrecan, with other proteins and glycoproteins in lesser amounts. This matrix allows normal cartilage to form the resilient, low-friction surface capable of absorbing shock with high impact mechanical loading (3). Within the ECM, collagen fibers provide form, shape, and tensile strength to cartilage. The principal collagen fibers present in articular cartilage are type II fibers, with smaller quantities of types V, VI, IX, X, and XI (1). Collagen interacts to form fibrils that interact with and trap large aggregates of PGs, principally aggrecan. PGs bind water and help
Metabolic disruption of cartilage homeostasis in osteoarthritis
Under normal conditions, chondrocytes maintain a dynamic equilibrium between synthesis and degradation of ECM components. In osteoarthritic states, however, there is a disruption of matrix equilibrium leading to progressive loss of cartilage tissue, clonal expansion of cells in the depleted regions, induction of oxidative states in a stressful cellular environment, and eventually, apoptosis of chondrocytes (2, 4) . With progression, there is usually an increase in both degradation and synthesis within the joint, with an overall shift toward catabolism over anabolism.
Chondrocyte metabolism is unbalanced due to excessive production of inflammatory cytokines and matrix-degrading enzymes, in conjunction with a downregulation of anabolic factors, eventually leading to destruction of the ECM and subsequent cartilage degradation. Oxidative stress elicited by reactive oxygen species (ROS) further disturbs cartilage homeostasis and promotes catabolism via induction of cell death, breakdown of matrix components, upregulation of latent matrix-degrading enzyme production, inhibition of ECM synthesis, and oxidation of intracellular and extracellular molecules (2) . One approach to slow or reverse catabolism involves attempts to downregulate the expression of catabolic factors and/or matrix-degrading enzymes, including matrix metalloproteases (MMPs) and a disintegrin-like and metalloprotease with thrombospondin motifs (ADAMTS family, aka aggrecanases)(5). In particular, MMP-13 is the most potent collagen type II-degrading enzyme in human articular cartilage (6). The regulation of matrix-degrading enzyme expression is stimulated by pro-inflammatory cytokines, growth factors, and metabolites, including lipopolysaccharide (LPS) (7), interleukin-1 (IL-1) (8), tumor necrosis factor-alpha (TNF-) (8), fibroblast growth factor-2 (FGF-2, otherwise known as basic FGF) (9), and ROS (10). Equally important are attempts to upregulate anabolic factors in matrix homeostasis, including ECM components (e.g., aggrecan, collagen type II), growth factors (e.g. transforming growth factor (TGF)-, bone morphogenetic proteins (BMPs), and insulin-like growth factor-1 (IGF-1)), and/or anti-destructive enzymes [e.g., tissue inhibitor of metalloproteases (TIMPs)] to prevent cartilage degradation.
Catabolic mediators in OA
Healthy articular chondrocytes and synoviocytes constitutively synthesize and secret a wide array of mediators to maintain their delicate homeostasis. When inappropriately regulated, a subset of mediators will drive detrimental catabolic processes in both cell populations, resulting in cartilage degeneration and chronic synovial inflammation. This section will summarize our current understanding of these key catabolic factors in OA pathogenesis.
Inflammatory mediators
Typical inflammatory mediators in OA include pro-inflammatory members from the interleukin family (IL-1, IL-6, and IL-17), TNF-, and prostaglandin E2 (PGE2). The roles of these mediators have been extensively studied in arthritic tissues secondary to their high concentrations in degenerative states. Each of these mediators not only stimulates the production of cartilage-degrading proteases, but also upregulates other destructive factors via paracrine or autocrine mechanisms, thus perpetuating disease progression.
IL-1β
IL-1 is thought to play a prominent role in OA development. It demonstrates potent bioactivities in inhibiting ECM synthesis and promoting cartilage breakdown. Independent studies have shown that IL-1 represses the expression of essential ECM components, aggrecan and collagen type II, in chondrocytes (11-13). IL-1 also strikingly induces a spectrum of proteolytic enzymes, including collagenases (MMP-1 and MMP-13) and ADAMTS-4, in both chondrocytes and synovial fibroblasts. Aside from these direct effects, IL-1 induces a panel of cytokines, including IL-6, IL-8, and leukemia inducing factor (LIF), which produce additive or synergistic effects in the catabolic cascade (14). Further, IL-1 has been implicated in OA pathogenesis in numerous observational studies. Although less pronounced than what has been observed in rheumatoid arthritis patients, OA synovial fluids contains significantly higher levels of IL-1 compared to normal synovial fluid (15) . Immunohistochemical analyses also reveal increased expression of IL-1 in OA cartilage and synovium (16, 17) . Moreover, osteoarthritic chondrocytes exhibit heightened sensitivity to IL-1 stimulation, in part due to augmented IL-1 receptor type I expression (18) . This pathological change renders OA chondrocytes even more susceptible to deleterious IL-1 attack. The significance of IL-1 in OA was further corroborated by in vivo studies and pharmaceutical efforts using IL-1 receptor antagonist (IL-1ra) as a potential therapeutic factor to prevent cartilage degeneration. As an inhibitory molecule of IL-1 , IL-1ra not only showed efficacy in OA animal models, but also improved clinical outcomes (19) .
IL-6
Another constitutively expressed cytokine in human articular chondrocytes is IL-6 (20), yet only a fraction of OA patients contains increased IL-6 levels in arthritic cartilage and synovial fluid, suggesting that IL-6 may not be the ultimate driving force in this disease (21, 22) . Nevertheless, in vitro studies demonstrate catabolic effects of IL-6 as this cytokine inhibits PG synthesis in chondrocytes, and this effect is potentiated by addition of soluble IL-6 receptor (sIL-6R) (23, 24) . Combination treatment with IL-6 and sIL-6R has been shown to enhance aggrecanase-mediated PG depletion in cartilage (25) . IL-6 also suppresses collagen type II expression (26) , and to a lesser extent than IL-1 , dysregulates enzymatic antioxidant defense mechanisms in chondrocytes via modulation of key enzymes (27) . Therefore, it is surprising that male IL-6 -/-mice displayed more severe OA phenotypes compared with wild-type mice (28). In this report, de Hooge et al suggest that IL-6 exerted joint protection in aging murine OA joints. However, their findings differ qualitatively from those provided by Ryu et al, who reported that IL-6 promotes joint destruction in an instability-induced OA model (29). Further in vivo experiments are warranted to clarify such contradictions. Interestingly, a recent study suggested a mechanistic link between obesity and OA, based on the observation that the infrapatellar fat pad actively synthesizes IL-6 and sIL-6R in knee OA patients (30).
IL-17
The pro-inflammatory role of IL-17 is well-established in rheumatoid arthritis, but less so in OA. IL-17 is reported to exert stimulatory effects on MMP-3, MMP-13 and ADAMTS-4 expression in chondrocytes (31, 32). It directly inhibits PG synthesis, augments nitric oxide production, and triggers angiogenic factor release (33-35). Further, the IL-17 response can be amplified dramatically when other destructive cytokines, such as IL-1 and TNF-, are present. In chondrocytes, IL-17-mediated type II collagen breakdown and MMP expression is synergistically enhanced by IL-1, IL-6, or TNF-co-treatment (36). Likewise, synergy in nitric oxide production was observed when chondrocytes were treated with IL-17 and TNF-(37). IL-17 also synergizes with IL-1 or TNF-in PGE2 production in OA menisci ex vivo (38). Cytokine induction serves as a secondary mechanism in IL-17-mediated effects. In chondrocytes and synovial fibroblasts, IL-17 induces certain pro-inflammatory cytokines and chemokines, such as IL-1 , IL-6, and IL-8 (39, 40). In macrophages, IL-17 effectively upregulates IL-1 and TNF-expression, which may contribute to chronic synovial inflammation observed in some OA patients (41) . By way of adenovirus-mediated IL-17 overexpression, Koenders et al. showed that IL-17 is capable of causing joint inflammation and bone erosion by itself, and also synergizes with TNF- (42) . Conversely, IL-17 deficiency markedly mitigates the arthritic phenotype in a collagen-induced arthritis model, but whether IL-17 ablation also provides similar protection in OA models awaits investigation (43).
TNF-α
The relevance of TNF-to OA pathogenesis is supported by the observation that TNFreceptor expression is significantly upregulated in OA cartilage (44, 45) . TNFconcentration in synovial fluid also increases in patients with anterior cruciate ligament injury, suggesting this cytokine may play a role in OA development (46) . Similar to IL-1 , TNF-also promotes PG depletion (47) (48) (49) . The induction of proteolytic enzymes MMP-3, MMP-9, and MMP-13 by TNF-in chondrocytes may account for such an action (50, 51) . TNF-potently induces IL-6 and PGE2, which possibly results in secondary inflammatory events in the joint (47, 48, 52, 53) . Another important process mediated by TNF-is cell death. It appears that excessive exposure to TNF-can elicit chondrocyte apoptosis, which will lead to local secondary necrosis and eventually a catabolic cascade due to absence of phagocytes in cartilage (54, 55) . Consistent with these findings, TNF-transgenic mice exhibit spontaneous cartilage damage and conspicuous occurrence of arthritis (54).
PGE2
PGE2 is yet another significant player in chondrocyte metabolism. Upregulated in OA, PGE2 inhibits PG and type II collagen synthesis with the highest cellular sensitivity among all prostanoids produced by chondrocytes (56, 57) . Mechanistically, PGE2 appears to signal through the EP2 receptor to exert such inhibitory effects (58 (59) . Interestingly, some evidence suggests that specific EP2 activation enhances cartilage regeneration in rabbit models, indicating species differences in PGE2 responses (60) . PGE2 also mediates or sensitizes chondrocytes to apoptosis (61, 62) . Both IL-1 and TNF-induce PGE2 production, with the former being more potent (63) (64) (65) , and the involvement of PGE2 in IL-1 -induced MMP-3 and MMP-13 expression is demonstrated in PGE synthase-1 knockout chondrocytes. In these modified cells, the catabolic effects of IL-1 are dramatically reduced (66) . However, another group claims that PGE2 acts as a secretagogue of IGF-1, which in turn mediates anabolism in chondrocytes (67) . Whether this induction brings any benefit to OA cartilage is questionable, because IGF-1 non-responsiveness has been reported in OA chondrocytes (68) .
Oxidative stress mediators, growth factors and glycoproteins 4.2.1 Nitric oxide
Nitric oxide (NO), a member of ROS, mediates the destructive actions of IL-1 and TNF-in cartilage, including suppression of PG and collagen synthesis, as well as stimulation of MMPs (69) (70) (71) (72) (73) . Spontaneous overproduction of NO produces similar effects in chondrocytes (73, 74) , and prolonged exposure to NO together with other ROS can lead to apoptosis of articular cell types (62, 75, 76) . NO is also partially responsible for the insensitivity of OA chondrocytes to IGF-1 (77) . As a mediator downstream of IL-1, NO also inhibits BMP-2-mediated PG synthesis (78) . Inducible nitric oxide synthase (iNOS) is the major enzyme responsible for NO generation in articular cartilage. OA chondrocytes in the superficial zone express higher levels of iNOS (79, 80) . Several destructive cytokines, including IL-1 and TNF-, induce iNOS expression in articular cell types (81, 82) . Forced expression of iNOS inhibits matrix synthesis in chondrocytes (74) . Futher, in OA cartilage, iNOS inhibition gives rise to IL-10 induction and MMP-10 repression in the presence of IL-1 (83). More recently, iNOS was found to function as a crucial mediator downstream of the advanced glycation end products pathway and the leptin pathway in chondrocytes (84, 85) . Pelletier et al provided compelling evidence regarding the importance of iNOS in OA progression. In their canine OA model, selective inhibition of iNOS resulted in marked attenuation of joint destruction (86) . Intra-articular delivery of an iNOS inhibitor counteracts the acute effects mediated by IL-1 , reaffirming the catabolic role of iNOS in OA progression (87).
FGF-2
A series of studies have demonstrated that FGF-2 (otherwise known as basic FGF) acts as a catabolic growth factor in addition to its well-established mitogenic role in articular cartilage. Despite its positive effect on proliferation, FGF-2 inhibits IGF-1/BMP-7-enhanced PG deposition in human articular chondrocytes, and negatively affects the physical properties of normal cartilage (88, 89) . FGF-2 alters the ratio of type II to type I collagen in articular chondrocytes, thus possibly leading to the formation of fibrocartilage, a poor substitute for hyaline cartilage (90, 91) . In porcine chondrocytes, FGF-2 antagonizes IGF-1/TGF--mediated decorin and type II collagen production (92) . Moreover, FGF-2 promotes cartilage degeneration ex vivo (93) . A mechanistic explanation of FGF-2-mediated effects lies in its ability to upregulate MMP-13 and ADAMTS-5 (94, 95). FGF-2 orchestrates the MAPK, NFκB, and substance P signaling pathway to induce MMP-13 (5, 93, 94) . It has also been 372 shown that activation of FGF receptor 1 (FGFR1) is required for FGF-2-mediated MMP-13 and ADAMTS-5 induction (95) . Results acquired from comparative analyses suggest the biological relevance of FGF-2 to OA. FGF-2 levels in OA synovial fluids are significantly elevated compared to those in normal specimens (94) . FGFR3 expression is markedly diminished in OA chondrocytes, which results in altered FGFR1 to FGFR3 ratios and may account for the inhibition of anabolism in the disease state (95) . It should be noted that other studies indicate a chondroprotective role of FGF-2 in cartilage biology (96, 97) . The discrepancies may arise from differences in cell origin (i.e. species, age, severity of OA, etc), and render future clarifications necessary.
Fibronectin
Fibronectin (Fn) is an adhesive glycoprotein found in cartilage and synovial membrane tissue (98). Evidence shows that Fn level is increased in OA cartilage as well as OA synovial fluid (99, 100) . Heightened proteolytic activities in OA joints lead to the generation of Fn fragments (Fn-fs) of different sizes. Specifically, ADAMTS-8 was characterized as a fibronectinase in OA chondrocytes (101) . Indeed, Fn-fs are found with increased abundance in OA synovial fluids and cartilage (99, 102) . A 40-kDa collagen-binding Fn-f induces sustained PG degradation in both normal and OA cartilage (103) . Furthermore, Fn-f stimulates type II collagen cleavage in an MMP-13-dependent manner (104) . Preceding collagen disintegration, Fn-f disrupts the ECM by promoting the release of cartilage oligomeric matrix protein (COMP) and chondroadherin (105) . Fn-f also augments cytokine, ROS, MMP and aggrecanase production in cartilage ex vivo and in vitro (10, 106-109). Stimulation of IL-1 leads to enhanced production of Fn-f, which exerts prolonged destructive effects (99).
Osteopontin
Osteopontin, a phosphorylated glycoprotein with cell and matrix binding affinities, has been characterized as a facilitator of osteoclast adhesion and an initiator of osteoid mineralization (110) . Osteopontin deposition in cartilage exhibits a spatial pattern, based on the fact that it is mainly detected in chondrocytes residing in the upper deep zone (111) . Comparative analyses reveal that, in contrast with healthy chondrocytes, OA chondrocytes express notable levels of osteopontin (111) . Moreover, an apparent correlation exists between osteopontin level and the severity of OA lesions (111) (112) (113) . Nevertheless, the role of osteopontin in cartilage remains controversial. Osteopontin promotes calcium pyrophosphate dehydrate (CPPD) crystal formation in articular cartilage, suggesting that elevated osteopontin production in OA may be detrimental (114) . Yet this stimulatory effect seems to depend on osteopontin concentration, because other studies demonstrate the opposite using higher concentrations of this protein (115) . Another independent study also showed that osteopontin inhibits IL-1 -induced NO and PGE2 production in OA cartilage, suggesting an anti-catabolic role in cartilage homeostasis (116) . Osteopontin deficiency exacerbates aging-induced and instabilityinduced OA in mice (117) . Based on these apparently contradictory activities, it raises the possibility that osteopontin elicits different biological effects depending on the stages of OA.
Osteonectin
Osteonectin is a non-collagenous glycoprotein linking collagen fibrils to mineral in bone. It is also present in mineralizing chondroid bone (118) . Articular chondrocytes synthesize osteonectin, and this process is regulated by endogenous stimuli. IL-1, TNF-, and FGF-2, but not IL-6, greatly inhibit osteonectin expression (119, 120) . IL-1 also impairs the glycosylation of osteonectin (120) . On the other hand, TGF-, PDGF, and IGF-1 upregulate osteonectin synthesis, even in the presence of IL-1 (119, 120) . Osteonectin is localized to the superficial and middle zones of OA cartilage, while normal cartilage does not display such a pattern (120, 121) . Osteonectin synthesis is also enhanced in OA synovial fibroblasts (120) . Osteonectin induces collagenase expression in this cell type, which may contribute to cartilage damage (122).
Protective mediators in OA
In contrast to the aforementioned catabolic mediators in OA, several growth factors take on important anabolic roles in the joint, thus serving as potential targets for future therapeutic growth factor therapy in practice. While the literature has only begun to explore the in vitro, in vivo, and clinical effects of many of these factors, there is potential for these mediators to be major players in the treatment of degenerative joint diseases in the future. Multiple cytokines exert protection in articular joints, including IL-1 receptor antagonist (IL-1ra), IL-4, IL-10, IL-11, and IL-13. Perhaps the most well-studied anabolic factors to date include TGF-, BMP-2, BMP-7, and IGF-1 (Table 1 ). We will also discuss two factors elucidated in our laboratory to have potent anabolic and anti-catabolic effects in human articular cartilage: resveratrol (RSV) and bovine lactoferricin (LfcinB).
Interleukins
The antagonistic effect of IL-1ra on IL-1 has been well established. By directly competing against IL-1 for its cognate receptor, IL-1ra effectively inhibits IL-1-mediated responses in chondrocytes, including PG depletion, MMP induction, and cytokine induction (123) (124) (125) . IL-1ra expression is repressed by NO, which may blunt its action in OA cartilage (126) . Not surprisingly, forced expression of IL-1ra confers resistance to IL-1 challenge in chondrocytes (127, 128) . Both gene delivery and IL-1ra intra-articular injection have been shown to impede OA progression, indicating anti-IL-1 therapy is a viable option in OA disease modification (19, 129) . Protective roles of anti-inflammatory cytokines have also been linked to OA. An array of cytokines, including IL-4, IL-10, IL-11, and IL-13, has been shown to block the actions of catabolic cytokines via different mechanisms. IL-4 suppresses MMP-13, cathepsin B, and iNOS when cyclic tensile stress is applied on chondrocytes (130, 131) . IL-4 has potent inhibitory effects on cartilage degradation in the presence of IL-1 and TNF- (132) . In synoviocytes, IL-4 downregulates apoptosis (133) . IL-4 gene therapy appears to dampen inflammation in chondrocytes (134) . Moreover, intra-articular injection of IL-4 results in notable amelioration of cartilage degenerative status (131) . IL-10 is upregulated in OA chondrocytes, and this phenomenon may represent a reparative effort (135) . IL-10 suppresses IL-1 and TNF-production (136) . Compared to IL-1ra, IL-10 gene delivery into synoviocytes elicits moderate yet still significant protection on cartilage (137). IL-11, an IL-6 family member, is believed to exert anti-catabolic and anti-inflammatory effects in articular joints, but remains poorly defined. IL-11 produced by articular chondrocytes stimulates the production of tissue inhibitor of metalloproteinase (TIMP) (138) . IL-11 also downregulates pro-inflammatory cytokines and NO production (139) . In OA synovial fibroblasts, IL-11 alone had no impact on PGE2 release, but shows antiinflammatory properties in conjunction with TNF- (140) . In RA synovium, IL-11 directly inhibits MMP-1 and MMP-3 production, upregulates TIMP-1, and inhibits TNFproduction in the presence of soluble IL-11 receptor (141) . Importantly, systemic treatment with IL-11 leads to a significant reduction in clinical and histological severity of established collagen-induced arthritis (CIA), suggesting an active role of IL-11 in joint homeostasis (142) . IL-11 level is greatly increased in OA synovial fluid (143) . However, IL-11 action is likely to be blunted due to the observation that the IL-11 receptor is markedly downregulated in OA chondrocytes (Im et al., unpublished data). IL-13 downregulates MMP-13 expression in OA chondrocytes (144) . Combined with IL-4, IL-13 abolishes IL-17 expression in RA synovial tissue (145) . A more detailed study revealed that IL-13 represses IL-1 , TNF-, and MMP-3, and simultaneously induces IL-1ra (146) . IL-13, as well as IL-4 and IL-10, reduces TNF--induced PGE2 release and cyclooxygenase 2 (COX-2) in OA synovial fibroblasts (147) . Similar to IL-4, IL-13 also inhibits synoviocyte apoptotic events (133) . Nonetheless, IL-13 levels were found to be low in OA tissues (148) . Whether IL-13 holds significance to OA pathogenesis needs to be further determined, especially in animal models.
IL-

TGF-/BMP Superfamily
The TGF-superfamily is composed of over 35 structurally-related members, with the majority of these members playing fundamental roles in development and homeostasis. In articular cartilage, three members of the TGF-superfamily have been shown to play a significant role in cartilage homeostasis: TGF-, BMP-2, and BMP-7. BMPs are structurally related to the transforming growth factor-(TGF-) superfamily and have wide-ranging biological activities, including the regulation of cellular proliferation, apoptosis, differentiation and migration, embryonic development and the maintenance of tissue homeostasis during adult life (149) (150) (151) . It is now clear that they are expressed in a variety of tissues including adult articular cartilage.
TGF-
Several studies demonstrate an anabolic role of TGF-β in articular cartilage. TGF-β has been shown to upregulate chondrocyte synthetic activity and suppress the catabolic activity of IL-1 (152, 153) . In vitro, TGF-β stimulates chondrogenesis of synovial lining and bone marrowderived mesenchymal stem cells (154) . Additionally, asporin inhibits TGF--mediated stimulation of cartilage matrix genes such as collagen type II and aggrecan, and inhibits accumulation of PGs (155) . In both Japanese (155) and Han Chinese (156) populations, patients with an asporin polymorphism demonstrated increased prevelance of arthritic conditions, presumably via inhibition of TGF-β expression, suggesting a protective role of TGF-β in articular cartilage. These findings were corroborated in knockout mice, as mice deficient for TGF-β or Smad3 (downstream mediator of TGF-β) developed cartilage degeneration resembling human OA (157, 158) . Other studies demonstrate a vital role of TGF-β in the suppression of NO and other ROS levels (159), as well as the upregulation of PG synthesis in calf-cartilage explants in a dose-dependent manner (152, 160) .
However, the literature also suggests that TGF-β demonstrates nondesirable side effects in joint tissues. For example, upon sustained exposure to in the joint, TGF-β can actually induce the formation of OA-like tissue pathology via stimulation of osteophyte formation, stimulation of synovial inflammation and fibrosis, and attraction of inflammatory leukocytes to the synovial lining (152, 153, 161, 162) . These contradictory findings warrant further investigation, and recent research efforts are focused on downstream receptor usage to help provide further clues (152) . Nevertheless, given its deleterious effects not seen in other growth factor-based strategies, TGF-therapy is not presently a viable option for use in articular cartilage repair or regeneration.
BMP-2
Several studies have analyzed the role of BMP-2 in cartilage and found promising results. The effect of BMP-2 on mesenchymal stem cells is similar to that of TGF-, with increased production of ECM and decreased expression of collage type 1, theoretically suppressing the formation of fibrocartilage (149, 154) . In vitro analysis reveals that BMP-2 stimulates matrix synthesis and reverses chondrocyte dedifferentiation as indicated by an increase in synthesis of cartilage-specific collagen type II in OA chondrocytes (163) . In rabbit knees, BMP-2-impregnated collagen sponges implanted into full-thickness cartilage defects enhance cartilage repair compared with empty defects or defects filled with collagen sponge alone, with this effect remaining at one year after implantation (164) . Interestingly, however, in an IL-1-induced cartilage degeneration model in mice, BMP-2 stimulated matrix production via increased collagen type II and aggrecan expression (anabolic activity), but also increased aggrecan degradation as well, revealing a possible catabolic or self-regulatory role (165) . Further studies are indeed warranted to further elucidate the effects of BMP-2 on cartilage repair.
BMP-7
BMP-7 (also known as osteogenic protein-1), another member of the TGF-superfamily, is perhaps the most well-studied anabolic growth factor in cartilage repair. It is expressed in cartilage and exerts potent anabolic effects by stimulating differentiation and metabolic functions of both osteocytes and chondrocytes (166) . In bone, a variety of animal models have clearly demonstrated a therapeutic potential of BMP-7 in bone repair applications, paving the way for BMP-7 to be used as the first commercial BMP to be used for bone repair clinically (149) . In articular cartilage, BMP-7 has potent anabolic effects by stimulating matrix biosynthesis in both human adult articular chondrocytes (167) and human IVD cells (168) .
In vitro, BMP-7 has several anabolic and anti-catabolic effects on articular cartilage. It promotes cell survival and upregulates chondrocyte metabolism (169) and protein synthesis without creating uncontrolled cell proliferation and formation of osteophytes, unlike other chondrogenic growth factors (149, 151) . In a comparison study examining BMP-2, -4, -6, and -7, as well as cartilage-derived morphogenetic protein (CDMP)-1 (also known as GDF-5, growth differentiation factor-5) and CDMP-2, PG synthesis was stimulated to a greater extent by BMP-2 and -4, and the most significant upregulation after stimulation with BMP-7 (150). Importantly, its actions in cartilage are age-independent as BMP-7 induced similar anabolic responses in normal and OA chondrocytes from both young and old donors without inducing chondrocyte hypertrophy or changes in phenotype (151, 170, 171) . Chubinskaya and colleagues have revealed that the anabolic effect of BMP-7 extends beyond stimulation of cartilage ECM proteins and their receptors, but also modulates the expression of various anabolic growth factors as well (IGF-1, TGF-/BMPs) (151) . In addition to its anabolic capacity, BMP-7 effectively counteracts chondrocyte catabolism, revealing a potent anti-catabolic effect in human articular cartilage. BMP-7 inhibits the expression of proinflammatory cytokines (IL-1 and IL-6), inhibits endogenous expression of cytokines (ie. IL-6, IL-8, IL-11) and their downstream signaling molecules (receptors, transcription factors, and mitogen-activated kinases), and blocks both a baseline and cytokine-induced expression of MMP-1 and MMP-13 (151). BMP-7 has also been shown to enhance the gene expression of the anabolic molecule tissue inhibitor of metalloproteinase (TIMP) in normal and OA chondrocytes (151) , and acts synergistically with the anabolic growth actors IGF-1 (169) and TGF- (172) . Data from animal studies reveal that BMP-7 clearly has therapeutic potential for cartilage repair. In a large chondral defect study in sheep cartilage, BMP-7 was shown to induce significant cartilage repair in a model where no repair takes place in the controls (173) . Studies evaluating models of OA, however, are less numerous, but BMP-7 has been shown to prevent development of damage and in some models reverse the damage (151) . Finally, although BMP-7 is highly effective at stimulating bone repair, it does not appear to lead to osteophyte formation when administered into a joint, nor does it stimulate uncontrolled fibroblast proliferation (leading to fibrosis) (149) . Studies have demonstrated that recombinant BMP-7 use has a relatively safe profile with few side effects in rabbits, dogs, goats and sheep. Overall, the data clearly indicate that BMP-7 has an important role in cartilage, both in normal homeostasis and in repair, but several unknowns continue to exist, such as concentration, dosing, the use of scaffolds, methods of administration, and possibly combinations with other factors.
IGF-1
IGF-1 is a single chain polypeptide that is structurally similar to insulin, a key growth factor that enhances PG synthesis in articular cartilage (174) . Much like BMP-7, IGF-1 has a promising future in the field of cartilage repair and regeneration therapy. In vitro, IGF-1 induces anabolic and anti-catabolic effects in normal articular cartilage from a variety of species (53, 175) . In vivo studies support in vitro findings, as IGF-1 deficiency in rats leads to the development of articular cartilage lesions (176) . In animal models, IGF-1 enhances repair of extensive cartilage defects and protects synovial membrane tissue from chronic inflammation (177, 178) . Other studies in spine cartilage demonstrate similar results. Osada et al showed that IGF-1 stimulates PG synthesis in bovine NP cells in serum-free conditions in a dose-dependent manner and proposed an autocrine/paracrine mechanism of action (179). Gruber and colleagues found that the addition of IGF-1 increased cell survival upon experimental induction of apoptosis in spine disc annulus fibrosus cells (180), consistent with the anti-catabolic capacity of IGF-1 in both intervertebral disc (IVD) and articular cartilage tissues. Despite its potent anabolic and anti-catabolic effects on normal cartilage tissue, however, IGF-1 appears to have a diminished ability to stimulate ECM formation and decrease catabolism with both age (181, 182) and OA (68, 149, 181 ). There appears to be an uncoupling of IGF-1 responsiveness in OA, as IGF-1 is able to stimulate matrix synthesis but is unable to decrease matrix catabolism (183) . Nevertheless, combination growth factor therapy with IGF-1 and BMP-7 results in greater repair potential than either factor alone (169) , and the effects of combination factor therapy on aged and old cartilage defects have yet to be determined.
Resveratrol
The phytoestrogen resveratrol (trans-3,4',5-trihydroxystilbene; RSV) is a natural polyphenol compound found in peanuts, cranberries, and the skin of red grapes, and is thought to be one of the compounds responsible for the health benefits of moderate red wine consumption (184, 185) . The anti-inflammatory, anti-oxidant, cardioprotective, and antitumor properties of RSV have been well-documented in a variety of tissues (186) (187) (188) (189) (190) (191) (192) (193) (194) , and recent studies have begun to analyze the effects of RSV on cartilage homeostasis. Elmali et al reported a significant protective effect of RSV injections on articular cartilage degradation in rabbit models for OA and RA via histological analysis in vivo (195, 196) . In human articular chondrocytes, Shakibaei (197) and Czaki (198) have elucidated both anti-apoptotic and antiinflammatory regulatory mechanisms mediated by RSV. In our laboratory, we have demonstrated potent anabolic and anti-catabolic potential of RSV in bovine spine nucleus pulposus IVD tissue (199) and human adult articular chondrocytes (Im et al., unpublished data) via inhibition of matrix-degrading enzyme expression at the transcriptional and translational level. Further, combination therapy of RSV with BMP-7 induces synergistic effects on PG accumulation, and RSV reverses the catabolic effects of FGF-2 and IL-1 on matrix-degrading enzyme expression, PG accumulation, and the expression of factors (iNOS, IL-1, IL-6) associated with oxidative stress and inflammatory states (199) . Future studies are needed to assess the appropriate dose, route of administration, and downstream effects of RSV, as well as elucidate its role in old or degenerative cartilage in vivo. Nevertheless, these findings reveal considerable promise for use of RSV as a unique biological therapy for treatment of cartilage degenerative diseases in the future.
Lactoferricin
Bovine lactoferricin (LfcinB) is a 25-amino acid cationic peptide with an amphipatic, antiparallel -sheet structure that is obtained by acid-pepsin hydrolysis of the N-terminal region of lactoferrin (Lf) found in cow's milk (200, 201) . It exerts more potent biological effects than equimolar amounts of Lf, is cell membrane-permeable, and interacts electrostatically with negatively-charged matrix and cell surface glycosaminoglycans (GAGs), heparin and chondroitin sulfate (200, 201) . The anti-inflammatory, anti-viral, anti-bacterial, anti-oxidant, anti-pain, and anti-cancer properties of LfcinB have been reported in a variety of tissues (202, 203) . The natural anti-oxidative effect of LfcinB has also been reported, suggesting a possible chondroprotective biological role in articular cartilage (204) , and several recent studies have attempted to elucidate the role of LfcinB in musculoskeletal disease. In a mouse collagen-induced and septic arthritis model, periarticular injection of human Lf substantially suppresses local inflammation (205) . Further, in a rat adjuvant arthritis model, oral administration of bovine Lf suppresses the development of arthritis and hyperalgesia in the adjuvant-injected paw, suggesting Lf has preventative and therapeutic effects on the adjuvant-induced inflammation and pain (206) . Human iron-free Lf delays the apoptosis of neutrophils isolated from synovial fluid of patients with established rheumatoid arthritis (207) . Lf was also identified as a novel bone growth factor, as local injection of Lf above the hemicalvaria of adult mice in vivo results in substantial increases in the dynamic histomorphometric indices of bone formation and bone area (208) .
Previously in our laboratory, LfcinB was found to exert potent anabolic and anti-catabolic effects in bovine nucleus pulposus matrix homeostasis in the IVD, similar to RSV (209) . Similar to the IVD, we also found similar anabolic and anti-catabolic effects of LfcinB in human articular cartilage (Im et al, unpublished data) . LfcinB reverses the catabolic effects of FGF-2 and IL-1 on matrix-degrading enzyme production, PG accumulation, and expression of factors associated with oxidative stress and inflammation, suggesting the promise of LfcinB as an anti-catabolic and anti-inflammatory molecule in human articular cartilage. Further, LfcinB abolishes the expression of iNOS, increases the expression of SOD-1, and antagonizes the catabolic effects mediated by bFGF and IL-1 on iNOS and SOD-1 expression, suggesting an anti-oxidative role of LfcinB in cartilage. Taken together, much like RSV, LfcinB may play an important role in prevention and treatment of diseases such as OA. Nevertheless, caution must be advised as further studies are warranted to determine, among other things, possible detrimental effects of its use in vivo.
Pain modulators in OA
Clinically, pain is the most prominent and disabling symptom of OA, and arthritic pain is associated with inferior functional outcomes and reduced quality of life compared with a range of other chronic conditions (210) . Like other chronic pain conditions, OA pain is a complex integration of sensory, affective and cognitive processes that involves a variety of abnormal cellular mechanisms at both peripheral (joints) and central (spinal and supraspinal) levels of the nervous system. For the development of new therapies aimed at pain relief, a thorough understanding of the pathological mechanisms eliciting pain in OA is required. Unfortunately, many of these mechanisms remain elusive because the primary site of pathology (i.e., articular cartilage) does not have neuronal pain receptors that can directly detect tissue injury due to mechanical damage. The process by which painful mechanical stimuli from arthritic joints are converted into electrical signals that propagate along sensory nerves to the central nervous system remains to be fully explored. Nociceptors are located throughout the joint in tissues peripheral to cartilage, including the joint capsule, ligaments, periosteum and subchondral bone. Joint cartilage and synovial injury influences peripheral afferent and dorsal root ganglion (DRG) neurons and sensitizes symptomatic pain perception through the dynamic interactions between neuropathic pathways and OA tissues. Nociceptive input from the joint is processed via different spinal cord pathways, and inflammation may potentially reduce the threshold for pain. The relative contribution of these processes into peripheral and central pathways appears to be strongly segmented (211) , with intra-articular anesthetic studies in hip and knee OA suggesting a peripheral drive to pain in approximately 60% to 80% of patients, depending on the affected joint (212) . In some individuals, however, central mechanisms such as dysfunction of descending inhibitory control or altered cortical processing of noxious information, may play a greater role (213) . Therefore, research and pharmacotherapy for OA pain may be separated into two broad classes: central sensitization and peripheral sensitization, both leading to one final outcome: pain in a patient with OA. A detailed overview of the multiple, complex pathways associated with OA pain, particularly relating to central sensitization mechanisms, is outside the scope of this chapter. For example, current targets of pharmacotherapy for OA pain are numerous and include opioids, kinins, cannabinoids, and their respective receptors, in addition to adrenergic receptors, glutamate receptors, specific ion channels, and neurotrophins. The literature is replete with data on the alteration of pain pathways via inhibition of both central and peripheral processes (211) . Here, we will focus on select pro-inflammatory cytokines and mediators previously discussed in this chapter, and report their known roles in pain processing. Our laboratory and others have mechanistically linked OA to pathological changes in the metabolism of ECM proteins and inflammatory states that may be controlled by epigenetic, epigenomic, and systemic processes involved in pain processing (5, 9, 89, 93, 94, 199, 214, 215) .
Cytokines
Inflammatory stimuli initiate a cascade of events, including the production of TNF-, interleukins, chemokines, sympathetic amines, substance P, leukotrienes and prostaglandins, each demonstrating a complex interplay with other mediators to induce pain (211, 216) . Cytokines stimulate hyperalgesia by a number of direct and indirect actions. Sensitization of primary afferent fibers for mechanical stimuli is thought to be induced by inflammatory mediators. IL-1 activates nociceptors directly via intracellular kinase activation, but it may also induce indirect nociceptor sensitization via the production of kinins and prostanoids (217) . IL-6, a well-known pro-inflammatory mediator, has been associated with hyperalgesia and hypersensitivity in articular cartilage (218) . As previously discussed, IL-6 plays an important role in the pathogenesis of rheumatoid arthritis, and its concentration is elevated in the serum and synovial fluid of arthritic patients (219, 220) . Interestingly, primary afferent neurons also respond to IL-6 (221), suggesting an important role of IL-6 in pain propagation in arthritic states. TNF-also activates sensory neurons directly via the receptors TNFR1 and TNFR2, and initiates a cascade of inflammatory reactions via the production of IL-1, IL-6 and IL-8 (217, 222) . Direct TNF-application in the periphery induces neuropathic pain, and this pain may be blocked by anti-inflammatory medications such as ibuprofen and celecoxib (223) . Anti-TNF-treatment with a TNF antibody produces a prolonged reduction of pain symptoms in OA (224) , and neutralization of TNF-in mice rescues both mechanical hyperalgesia (testing of withdrawal responses in behavioral experiments) and the inflammatory process (225) . Taken together, TNF-induces an algesic effect, at least in part, via both neuronal and inflammatory stimulation. Antagonists to TNF-, such as etanercept or infliximab, may indeed serve as a potential therapeutic strategy to decrease OA pain clinically (211) . Further controlled studies are needed to substantiate these promising preliminary data on TNF inhibitors in OA.
Prostanoids and PGE2
During pro-inflammatory states, numerous prostanoid cyclooxygenase (COX) enzyme products are produced and released, including PGE2, PGD2, PGF2a, thromboxane, and PGI2 (211) . These factors serve as the premise for blocking the major synthetic enzymes COX-1 and COX-2 with selective or non-selective COX-inhibitor medications (ie. nonsteroidal anti-inflammatory drugs) (226) . Of these mediators, PGE2 is considered to be the major contributor to inflammatory pain in arthritic conditions. PGE2 exerts its effects via a variety of E prostanoid (EP) receptors (EP1, EP2, EP3, EP4), which are present in both peripheral sensory neurons and the spinal cord (211) . Activation of these receptors produces a variety of effects, ranging from calcium influx to cAMP activation or inhibition.
Peripherally, sensitization of nociceptors by PGE2 is caused by the cAMP-mediated enhancement of sodium currents after ion channel phosphorylation (227) . However, in the spinal cord, PGE2 acts via different receptors than peripherally, suggesting further complexity in the prostanoid regulation of pain (228) .
In our laboratory, we have assessed the role of PGE2 in human adult articular cartilage homeostasis and its relation to possible pain pathways (58) . PGE2 utilizes the EP2 and EP4 receptors downstream to induce its downstream catabolic effects, and PGE2 may mediate pain pathways in articular cartilage via its stimulatory effect on the pain-associated factors IL-6 (218) and iNOS (229) . Further, when combined with the catabolic cytokine IL-1, PGE2 synergistically upregulates both IL-6 and iNOS mRNA levels in vitro (58) . Similar synergistic results were found with iNOS expression as well. Therefore, the EP2/4 receptor may be an important signaling initiator of the PGE2-signaling cascade and a potential target for therapeutic strategies aimed at preventing progression of arthritic disease and pain in the future. As opposed to PGE2 EP receptor blockade, an alternative route of PGE2 inhibition is via the blockade of PGE synthase (PGES), a major route of conversion of prostaglandin H2 to PGE2 (211) . Two isoforms of the enzyme have been identified, membrane or microsomal associated (mPGES-1) and cytosolic (cPGES/p23), which are linked with COX-2 and COX-1 dependent PGE2 production, respectively (230) . Both isoforms are upregulated by inflammatory mediators, and gene deletion studies in mice indicate an important role for mPGES in acute and chronic inflammation and inflammatory pain, revealing a potential target for pain treatment in OA (211, 231).
Discussion
In summary, the literature reveals important roles of catabolic and anabolic growth factors and cytokines in articular cartilage homeostasis and the development of OA. Each factor discussed plays a critical role in cartilage, both in normal homeostasis and in repair. Currently, many of these specific roles remain unknown, but recent efforts have begun to increase our understanding. Catabolic factors include pro-inflammatory mediators (IL-1, IL-6, IL-17, TNF-and PGE2), oxidative mediators (iNOS), glycoproteins (fibronectin, osteonectin, and osteopontin), and even growth factors (FGF-2). In contrast, anabolic mediators include select interleukins, TGF-, IGF-1, BMPs (BMP-2 and BMP-7), RSV and LfcinB. Upregulation of catabolic processes and/or downregulation of anabolic processes leads to disruption of equilibrium with subsequent cartilage degradation and OA, and several of these pathways are known to induce pain in OA as well (ie. IL-1, IL-6, NO, TNF-, PGE2). The goal of biologic therapy is to retard this process via inhibition of catabolic processes and upregulation of anabolic processes with the hope of clinically preserving joint cartilage, thereby slowing or preventing the process of OA. Despite a tremendous research effort in recent years to elucidate these processes, however, biologic therapy for OA remains experimental in nature, and several unknowns exist. Given the wide array of interactions of growth factors that are necessary for proper cartilage development and homeostasis in vivo, it is unlikely that any single growth factor will lead to complete cartilage repair or affect the arthritic joint clinically, and rather a combination approach will be required (149) . Further, appropriate dosing, scaffolds, and routes of administration must be determined before any of these factors plays a role clinically. Nevertheless, this chapter reviews several of the most well-studied biochemical mediators involved in OA and provides a framework for the understanding of potential biologic therapies in the treatment of degenerative joint disease in the future. 
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